SCHEMBL5607278

SCHEMBL5607278

CCOC(=O)c1nc(-c2ccccc2Oc2ccc(C)cc2O)no1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.54
MAPT P10636 4/20 0.43
ALDH1A1 P00352 6/20 0.41
TSHR P16473 5/20 0.41
NPSR1 Q6W5P4 4/20 0.41
KDM4E B2RXH2 4/20 0.41
HSD17B10 Q99714 4/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.39
HPGD P15428 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
ALOX5 P09917 1/20 0.38
HCRTR1 O43613 2/20 0.37
HCRTR2 O43614 2/20 0.37
TP53 P04637 2/20 0.37
MEN1 O00255 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5606269 0.90 HTT (0.52) HTTMAPTALDH1A1TSHRNPSR1
SCHEMBL5606882 0.87 MAPT (0.43) HTTMAPTALDH1A1TSHRNPSR1
SCHEMBL5607392 0.84 HTT (0.48) HTTMAPTALDH1A1LMNAHPGD
SCHEMBL5606872 0.82 HTT (0.64) HTTMAPTALDH1A1TSHRNPSR1
SCHEMBL5606412 0.82 HTT (0.50) HTTMAPTALDH1A1TSHRNPSR1
SCHEMBL10147437 0.77 HTT (0.58) HTTMAPTALDH1A1TSHRNPSR1
SCHEMBL5606878 0.76 NPC1 (0.41) HTTALDH1A1TSHRNPSR1KDM4E
SCHEMBL5142594 0.76 HTT (0.52) HTTMAPTTSHRNPSR1KDM4E
SCHEMBL5606613 0.75 HTT (0.59) HTTMAPTALDH1A1KDM4ELMNA
SCHEMBL5607655 0.74 TTR (0.46) MAPTALDH1A1TSHRNPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP claimed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US claimed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO claimed
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP disclosed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US disclosed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents TYR, NFE2L2, CYP1A1 HTT 4799/4885MAPT 4105/4885ALDH1A1 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.